We confirmed the specificity and involvement of the NAD+ metabolism in the combination of olaparib and daporinad by rescue experiments using NMN (the product of the activity of NAMPT), which was also observed when an NAMPT inhibitor was used as a single agent in other ovarian cancer cell lines32. This evidence concerns the gene NAMPT and ovarian carcinoma.